Related Experiment Video
Updated: Jun 5, 2026

Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
Evolving landscape of targeted immunotherapeutic interventions and CAR-T therapy for acute myeloid leukemia
Tara Chand Yadav1, Shanid Mohiyuddin1, Gerhard C Hildebrandt1
1Division of Hematology and Medical Oncology, Department of Medicine, Ellis Fischel Cancer Center, University of Missouri, Columbia, MO, USA.
Abstract:
Acute myeloid leukemia is an aggressive and heterogeneous disease characterized by abnormal proliferation of leukemic blast cells and niche remodeling. Traditional therapies fail to manage evolving and resistant AML subtypes. Next-generation immunotherapeutic interventions, such as CAR-T cells, immune checkpoint inhibitors, antibody-drug conjugates, and antibody-based therapeutics, target leukemic blast cells. This review aims to provide a comprehensive overview of the evolving landscapes of immunotherapeutic strategies, challenges, and breakthroughs in tackling AML.
More Related Videos
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
09:34Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
Published on: February 17, 2022
Related Concept Videos
Tumor Immunotherapy
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...